Anti-angiogenesis therapy:concepts and importance of dosing schedules in clinical trials
1Tumor Biology Center at the Albert-Ludwigs University Freiburg
Abstract:
The biological control of angiogenesis is critical to the clinical control of cancer. Understanding the mechanism of formation and regulation of new blood vessel development would open a new avenue for cancer treatment. Intense research effort has revealed a variety of factors which initiate, control and terminate the multi-stage process of angiogenesis, as well as target structures which interfere with this process. Protease inhibitors, inhibitors of the endothelial cell proliferation, suppressors of angiogenic growth factors, copper chelators, and other compounds interfering with the process of angiogenesis were screened for inhibition of tumor angiogenesis and some of them are in clinical trials. Very recently, a new term, 'metronomic dosing regimen' has been introduced, which implicates the use of the old cytostatic anticancer agents as anti-angiogenic agents. Results from recent studies will be discussed briefly and the prospects of inhibition of tumor angiogenesis as a new treatment modality will be outlined. Copyright 2000 Harcourt Publishers Ltd.
Insights
Controlling new blood vessel growth (angiogenesis) is key to cancer treatment. Researchers are exploring various compounds and metronomic dosing to inhibit tumor angiogenesis, offering new therapeutic strategies.
Area of Science:
- Oncology
- Vascular Biology
Background:
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and progression.
- Understanding the intricate mechanisms regulating angiogenesis is vital for developing effective cancer therapies.
Purpose of the Study:
- To review the biological control of angiogenesis in cancer.
- To outline novel therapeutic strategies targeting tumor angiogenesis.
Main Methods:
- Screening of various compounds, including protease inhibitors, endothelial cell proliferation inhibitors, angiogenic growth factor suppressors, and copper chelators, for their ability to inhibit tumor angiogenesis.
- Discussion of the emerging concept of metronomic dosing regimens using conventional cytostatic agents as anti-angiogenic therapies.
Main Results:
- Several classes of compounds have demonstrated inhibitory effects on tumor angiogenesis and are currently undergoing clinical trials.
- Metronomic dosing represents a novel approach utilizing existing chemotherapy drugs for anti-angiogenic purposes.
Conclusions:
- Inhibition of tumor angiogenesis presents a promising new modality for cancer treatment.
- Further research and clinical evaluation are warranted to optimize anti-angiogenic strategies.
More Related Videos
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Related Concept Videos
Dosage Regimen: Individualization
Dosage Regimens: Designs and Approaches
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
